東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Improving Quantification and Charact...

Zammit, Matthew D.

Linked to FindBook

Google Book

Amazon

博客來

Improving Quantification and Characterization of Alzheimer's Disease Biomarkers in Down Syndrome Using PETD Imaging.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Improving Quantification and Characterization of Alzheimer's Disease Biomarkers in Down Syndrome Using PETD Imaging./
Author:	Zammit, Matthew D.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2021,
Description:	133 p.
Notes:	Source: Dissertations Abstracts International, Volume: 83-01, Section: B.
Contained By:	Dissertations Abstracts International83-01B.
Subject:	Medical imaging. -
Online resource:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28546862
ISBN:	9798516925559

Improving Quantification and Characterization of Alzheimer's Disease Biomarkers in Down Syndrome Using PETD Imaging.
Zammit, Matthew D.

Improving Quantification and Characterization of Alzheimer's Disease Biomarkers in Down Syndrome Using PETD Imaging. - Ann Arbor : ProQuest Dissertations & Theses, 2021 - 133 p.

Source: Dissertations Abstracts International, Volume: 83-01, Section: B.

Thesis (Ph.D.)--The University of Wisconsin - Madison, 2021.

This item must not be sold to any third party vendors.

Positron emission tomography (PET) has recently emerged as a powerful tool to investigate the progression of Alzheimer's disease (AD) throughout both its clinical and preclinical phases. The field of AD research has emphasized the use of PET to characterize the progression of amyloid-β plaques (Aβ), neurofibrillary tangles (NFTs) and neurodegeneration. This dissertation details the characterization of AD biomarker progression in Down syndrome (DS) using [11C]PiB PET for Aβ, [18F]AV-1451 PET for NFTs, and [18F]FDG PET for glucose metabolism/neurodegeneration. To improve Aβ PET quantification, the amyloid load metric (AβL) was explored and compared to the more conventional standardized uptake value ratio metric (SUVr). The longitudinal AβL data was used to identify the earliest stages of Aβ accumulation in DS, and rates of Aβ change were compared to late-onset AD. Using AV-1451 PET, NFT progression in DS was explored across the conventional Braak staging of NFT pathology in late-onset AD. AV-1451 scores were compared against different groups of DS based on Aβ status to identify whether individuals with DS in the earliest stages of Aβ progression display early NFT progression. Finally, FDG PET was evaluated as a potential marker of neurodegeneration in DS. Glucose metabolism in DS was explored in relation to Aβ using FDG across typically affected regions in late-onset AD. FDG was directly compared to neuropsychological measures of cognition that have been validated for use in DS to monitor AD-related cognitive decline. Using PiB PET, the AβL metric allowed for improved quantification of Aβ in DS compared to the conventional SUVr. With AβL, PET was able to identify Aβ accumulation much earlier than previously achievable in the preclinical AD phase. When combined with NFT PET, these early Aβ accumulators evidenced significant NFT pathology in the early Braak stage regions, potentially indicating that these biomarkers emerge at the same time during AD progression. With FDG PET, glucose hypometabolism was highly associated with measures of cognitive decline. The findings presented in this dissertation highlight the utility of PET imaging for early detection of AD biomarker progression and for characterization of the preclinical and clinical stages of AD in DS.

ISBN: 9798516925559Subjects--Topical Terms:

3172799
Medical imaging.
Subjects--Index Terms:

Alzheimer's disease

Improving Quantification and Characterization of Alzheimer's Disease Biomarkers in Down Syndrome Using PETD Imaging.
LDR:03492nmm a2200349 4500 001 2281793
005 20210920103409.5
008 220723s2021 ||||||||||||||||| ||eng d
020 $a 9798516925559
035 $a (MiAaPQ)AAI28546862
035 $a AAI28546862
040 $a MiAaPQ $c MiAaPQ
100 1 $a Zammit, Matthew D. $3 3560505
245 1 0 $a Improving Quantification and Characterization of Alzheimer's Disease Biomarkers in Down Syndrome Using PETD Imaging.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2021
300 $a 133 p.
500 $a Source: Dissertations Abstracts International, Volume: 83-01, Section: B.
500 $a Advisor: Christian, Bradley T.
502 $a Thesis (Ph.D.)--The University of Wisconsin - Madison, 2021.
506 $a This item must not be sold to any third party vendors.
520 $a Positron emission tomography (PET) has recently emerged as a powerful tool to investigate the progression of Alzheimer's disease (AD) throughout both its clinical and preclinical phases. The field of AD research has emphasized the use of PET to characterize the progression of amyloid-β plaques (Aβ), neurofibrillary tangles (NFTs) and neurodegeneration. This dissertation details the characterization of AD biomarker progression in Down syndrome (DS) using [11C]PiB PET for Aβ, [18F]AV-1451 PET for NFTs, and [18F]FDG PET for glucose metabolism/neurodegeneration. To improve Aβ PET quantification, the amyloid load metric (AβL) was explored and compared to the more conventional standardized uptake value ratio metric (SUVr). The longitudinal AβL data was used to identify the earliest stages of Aβ accumulation in DS, and rates of Aβ change were compared to late-onset AD. Using AV-1451 PET, NFT progression in DS was explored across the conventional Braak staging of NFT pathology in late-onset AD. AV-1451 scores were compared against different groups of DS based on Aβ status to identify whether individuals with DS in the earliest stages of Aβ progression display early NFT progression. Finally, FDG PET was evaluated as a potential marker of neurodegeneration in DS. Glucose metabolism in DS was explored in relation to Aβ using FDG across typically affected regions in late-onset AD. FDG was directly compared to neuropsychological measures of cognition that have been validated for use in DS to monitor AD-related cognitive decline. Using PiB PET, the AβL metric allowed for improved quantification of Aβ in DS compared to the conventional SUVr. With AβL, PET was able to identify Aβ accumulation much earlier than previously achievable in the preclinical AD phase. When combined with NFT PET, these early Aβ accumulators evidenced significant NFT pathology in the early Braak stage regions, potentially indicating that these biomarkers emerge at the same time during AD progression. With FDG PET, glucose hypometabolism was highly associated with measures of cognitive decline. The findings presented in this dissertation highlight the utility of PET imaging for early detection of AD biomarker progression and for characterization of the preclinical and clinical stages of AD in DS.
590 $a School code: 0262.
650 4 $a Medical imaging. $3 3172799
650 4 $a Neurosciences. $3 588700
653 $a Alzheimer's disease
653 $a Biomarkers
653 $a Down syndrome
653 $a Positron emission tomography (PET)
690 $a 0574
690 $a 0317
710 2 $a The University of Wisconsin - Madison. $b Medical Physics. $3 2097834
773 0 $t Dissertations Abstracts International $g 83-01B.
790 $a 0262
791 $a Ph.D.
792 $a 2021
793 $a English
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28546862